Gerresheimer (GXI) Hisse Özeti
Gerresheimer AG, iştirakleri ile birlikte Almanya'da ve uluslararası alanda ilaç ambalajları, ilaç dağıtım cihazları ve çözümleri üretmekte ve satmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 1/6 |
| Finansal Sağlık | 0/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
GXI Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Gerresheimer AG Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | €27.32 |
| 52 Haftanın En Yüksek Seviyesi | €66.50 |
| 52 Haftanın En Düşük Seviyesi | €14.83 |
| Beta | 0.45 |
| 1 Aylık Değişim | 27.90% |
| 3 Aylık Değişim | 33.66% |
| 1 Yıllık Değişim | -53.30% |
| 3 Yıllık Değişim | -73.22% |
| 5 Yıllık Değişim | -69.88% |
| Halka arzdan bu yana değişim | -28.76% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • May 03
GXI: FY25 Warning And Deferred Results Will Drive Further Share Weakness
Analysts have trimmed their average price target for Gerresheimer to about €12.90 from €29, citing reduced short- and mid-term estimates following the recent FY25 warning and slightly softer expectations compared with the low end of the company's FY26 guidance. Analyst Commentary Bearish analysts are flagging a more cautious stance on Gerresheimer, pointing to reduced confidence in near term execution and visibility.
Anlatı Güncellemesi • Apr 19
GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.
Anlatı Güncellemesi • Apr 05
GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.Anlatı Güncellemesi • Mar 22
GXI: FY25 Warning And Deferred Results Will Pressure Shares Further
Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.Recent updates
Anlatı Güncellemesi • May 03
GXI: FY25 Warning And Deferred Results Will Drive Further Share Weakness
Analysts have trimmed their average price target for Gerresheimer to about €12.90 from €29, citing reduced short- and mid-term estimates following the recent FY25 warning and slightly softer expectations compared with the low end of the company's FY26 guidance. Analyst Commentary Bearish analysts are flagging a more cautious stance on Gerresheimer, pointing to reduced confidence in near term execution and visibility.Anlatı Güncellemesi • Apr 19
GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.Anlatı Güncellemesi • Apr 05
GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.Anlatı Güncellemesi • Mar 22
GXI: FY25 Warning And Deferred Results Will Pressure Shares Further
Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.Anlatı Güncellemesi • Mar 07
GXI: Reset After FY25 Warning Will Set Up Future Earnings Reappraisal
Analysts have reduced their price target for Gerresheimer to about €46 from about €52, citing a higher discount rate and lower assumed future P/E, along with updated revenue growth and profit margin assumptions, as well as recent cautious Street research following the FY25 warning. Analyst Commentary The latest Street research has turned more cautious after the FY25 warning, with at least one major broker shifting to a Sell stance and cutting its price target to €12.90 from €29.Anlatı Güncellemesi • Feb 21
GXI: Deferred Results And Softer Outlook Will Keep Shares Fairly Priced
Analysts have adjusted their price target on Gerresheimer to €18.90 from €22.00 as they now apply a slightly higher discount rate, a lower assumed revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Gerresheimer issued earnings guidance for 2026, targeting revenues of around €2.3b to €2.4b (company guidance).Analiz Makalesi • Feb 10
Investors Don't See Light At End Of Gerresheimer AG's (ETR:GXI) Tunnel
Gerresheimer AG's ( ETR:GXI ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a buy right now compared...Anlatı Güncellemesi • Feb 06
GXI: Index Inclusion And Higher P/E Assumptions Will Support Long-Term Confidence
Analysts have modestly lifted their price target for Gerresheimer, citing small adjustments to fair value and discount rate assumptions, as well as revised expectations for revenue growth, profit margins and future P/E. What's in the News Gerresheimer AG has been added to the Germany SDAX (Total Return) Index, highlighting its inclusion in this segment of the German equity market (Key Developments).Anlatı Güncellemesi • Jan 23
GXI: Reset Expectations Will Set Up Future Reappraisal Of Earnings Quality
Analysts have trimmed their average price target on Gerresheimer to €30 from €55. The change reflects updated expectations for revenue growth, profit margins and future P/E multiples following recent research reviews.Anlatı Güncellemesi • Jan 09
GXI: Profit Warnings Reset Expectations While Drug Delivery Platform Will Drive Reassessment
Gerresheimer's updated fair value estimate has been cut from about €97.07 to around €51.97 as analysts reset price targets sharply lower, citing reduced earnings visibility, a higher discount rate and increased uncertainty following recent profit warnings and rating downgrades. Analyst Commentary Recent Street research has turned more cautious on Gerresheimer, with several firms lowering price targets and adjusting ratings following profit warnings and reduced visibility on the investment case.Anlatı Güncellemesi • Dec 25
GXI: Profit Warnings And Weak Outlook Will Pressure Shares Further
Gerresheimer's analyst price target has been cut sharply from about EUR 47.50 to EUR 22.00, as analysts factor in lower growth, thinner margins, a higher discount rate, and reduced valuation multiples following multiple target downgrades and rising uncertainty around the investment case. Analyst Commentary Bearish analysts have made a series of aggressive downward revisions to Gerresheimer's valuation, cutting price targets from prior levels as high as EUR 99.30 to a range between EUR 23 and EUR 46.Anlatı Güncellemesi • Dec 11
GXI: Long-Term Sector Demand Will Support Confidence Despite Recent Profit Warnings
Analysts have cut their price target on Gerresheimer sharply, from roughly EUR 35 to about EUR 34. This reflects reduced fair value estimates as they factor in lower visibility on the investment case, successive target downgrades across the Street, and ongoing uncertainty following multiple profit warnings.Analiz Makalesi • Nov 30
These 4 Measures Indicate That Gerresheimer (ETR:GXI) Is Using Debt In A Risky Way
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Anlatı Güncellemesi • Nov 27
GXI: Long-Term Sector Demand Will Support Confidence After Recent Leadership Change
Gerresheimer's analyst price targets have been significantly reduced recently, with analysts citing ongoing uncertainties and diminished near-term visibility as key factors for the downward revision. Previous targets exceeded €50, but new values are now in the €23 to €46 range.Anlatı Güncellemesi • Nov 10
GXI: Confidence Will Remain Despite Current Uncertainties And Leadership Transition
Gerresheimer's analyst fair value target has been revised downward from €37.84 to €34.62. This change reflects recent broad cuts in price targets by analysts, who cite low visibility and ongoing uncertainties around the company's outlook.Analiz Makalesi • Nov 02
Lacklustre Performance Is Driving Gerresheimer AG's (ETR:GXI) 27% Price Drop
To the annoyance of some shareholders, Gerresheimer AG ( ETR:GXI ) shares are down a considerable 27% in the last...Anlatı Güncellemesi • Oct 27
Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead
Gerresheimer's analyst price target has been significantly reduced from €56.36 to €37.84. Analysts cite heightened uncertainties, reduced growth expectations, and a lack of near-term catalysts as reasons for this more cautious outlook.Anlatı Güncellemesi • Oct 13
New Production Lines In Lohr And Skopje Will Improve Efficiency
Analysts have lowered their price target for Gerresheimer from €63.72 to €56.36. They cite more cautious expectations for revenue growth and profitability going forward.Anlatı Güncellemesi • Sep 23
New Production Lines In Lohr And Skopje Will Improve Efficiency
The downward revision in Gerresheimer’s price target reflects recent declines in both net profit margin and consensus revenue growth forecasts, resulting in a reduced fair value estimate from €66.84 to €63.72. What's in the News Wolf Lehmann appointed as incoming CFO, succeeding Dr. Bernd Metzner; Lehmann brings nearly 30 years of international finance and management experience.Analiz Makalesi • Sep 18
Why We're Not Concerned About Gerresheimer AG's (ETR:GXI) Share Price
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Analiz Makalesi • Jul 31
Here's Why Gerresheimer (ETR:GXI) Is Weighed Down By Its Debt Load
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jun 18
Positive Sentiment Still Eludes Gerresheimer AG (ETR:GXI) Following 28% Share Price Slump
Unfortunately for some shareholders, the Gerresheimer AG ( ETR:GXI ) share price has dived 28% in the last thirty days...Analiz Makalesi • May 30
Shareholders May Be Wary Of Increasing Gerresheimer AG's (ETR:GXI) CEO Compensation Package
Key Insights Gerresheimer's Annual General Meeting to take place on 5th of June Salary of €1.15m is part of CEO Dietmar...Analiz Makalesi • May 29
Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Gerresheimer AG ( ETR:GXI ) will pay a dividend of €1.25 on the 10th of June. Based on this payment, the dividend yield...Analiz Makalesi • May 14
Is There Now An Opportunity In Gerresheimer AG (ETR:GXI)?
Gerresheimer AG ( ETR:GXI ), is not the largest company out there, but it led the XTRA gainers with a relatively large...Analiz Makalesi • Apr 24
Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Gerresheimer AG ( ETR:GXI ) has announced that it will pay a dividend of €1.25 per share on the 10th of June. Based on...Analiz Makalesi • Apr 19
Earnings Troubles May Signal Larger Issues for Gerresheimer (ETR:GXI) Shareholders
Gerresheimer AG's ( ETR:GXI ) recent weak earnings report didn't cause a big stock movement. However, we believe that...Analiz Makalesi • Apr 11
It's Down 32% But Gerresheimer AG (ETR:GXI) Could Be Riskier Than It Looks
Gerresheimer AG ( ETR:GXI ) shares have had a horrible month, losing 32% after a relatively good period beforehand. The...Analiz Makalesi • Apr 10
Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
Gerresheimer AG's ( ETR:GXI ) investors are due to receive a payment of €1.25 per share on 10th of June. This means the...Analiz Makalesi • Mar 05
Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
The board of Gerresheimer AG ( ETR:GXI ) has announced that it will pay a dividend on the 10th of June, with investors...Analiz Makalesi • Feb 25
Why Investors Shouldn't Be Surprised By Gerresheimer AG's (ETR:GXI) 25% Share Price Surge
Gerresheimer AG ( ETR:GXI ) shareholders would be excited to see that the share price has had a great month, posting a...
Yeni Anlatı • Feb 09
Expansion Into High-Margin Biologics And Devices Indicates Strong Future Prospects
Strategic expansion into high-margin segments like drug delivery systems and ready-to-use vials could enhance revenue and EBITDA margins significantly.Analiz Makalesi • Jan 12
Is Gerresheimer (ETR:GXI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Dec 26
Is It Time To Consider Buying Gerresheimer AG (ETR:GXI)?
While Gerresheimer AG ( ETR:GXI ) might not have the largest market cap around , it saw significant share price...Analiz Makalesi • Oct 03
Gerresheimer AG Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next
It's been a mediocre week for Gerresheimer AG ( ETR:GXI ) shareholders, with the stock dropping 20% to €77.50 in the...Analiz Makalesi • Sep 29
Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analiz Makalesi • Aug 31
Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 31x Gerresheimer AG ( ETR:GXI ) may be sending very bearish signals at the...Hissedar Getirileri
| GXI | DE Life Sciences | DE Pazar | |
|---|---|---|---|
| 7D | 10.9% | 11.9% | 3.2% |
| 1Y | -53.3% | -10.8% | 2.5% |
Getiri vs. Endüstri: GXI geçen yıl % -10.8 oranında getiri sağlayan German Life Sciences sektörünün gerisinde kaldı.
Getiri vs Piyasa: GXI geçen yıl % 2.5 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| GXI volatility | |
|---|---|
| GXI Average Weekly Movement | 13.1% |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.6% |
| 10% least volatile stocks in DE Market | 2.7% |
İstikrarlı Hisse Senedi Fiyatı: GXI hisse senedi fiyatı, son 3 ayda German piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: GXI 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1864 | 13,535 | Uwe Röehrhoff | www.gerresheimer.com |
Gerresheimer AG, iştirakleri ile birlikte Almanya'da ve uluslararası alanda ilaç ambalajları, ilaç dağıtım cihazları ve çözümleri üretmekte ve satmaktadır. Üç bölüm aracılığıyla faaliyet göstermektedir: Plastikler ve Cihazlar, Birincil Ambalaj Camı ve İleri Teknolojiler. Şirket, önceden doldurulabilir şırıngalar, plastik ve cam ambalaj çözümleri, flakonlar, cam kartuşlar ve ampuller, şişeler ve kaplar ve cam şişeler ve kavanozların yanı sıra kapaklar, kapaklar, aplikatörler ve aksesuarlar; ilaç dağıtım programlarının geliştirilmesi, sanayileştirilmesi ve fason üretimi; proje ve kalite yönetimi; ve inhalerler, enjeksiyon / otomatik enjektörler, kalem enjektörler, infüzyon sistemleri ve inhalasyon değerlendirmesi, otomatik enjektör ve diğer hizmetler dahil olmak üzere ilaç dağıtım sistemleri sunmaktadır.
Gerresheimer AG Temel Bilgiler Özeti
| GXI temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | €943.63m |
| Kazançlar(TTM) | €23.35m |
| Gelir(TTM) | €2.25b |
40.4x
F/K Oranı0.4x
P/S OranıGXI aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| GXI gelir tablosu (TTM) | |
|---|---|
| Gelir | €2.25b |
| Gelir Maliyeti | €1.65b |
| Brüt Kâr | €605.15m |
| Diğer Giderler | €581.80m |
| Kazançlar | €23.35m |
Son Raporlanan Kazançlar
Aug 31, 2025
Sonraki Kazanç Tarihi
Jul 14, 2026
| Hisse başına kazanç (EPS) | 0.68 |
| Brüt Marj | 26.89% |
| Net Kâr Marjı | 1.04% |
| Borç/Özkaynak Oranı | 155.5% |
GXI uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
0.1%
Mevcut Temettü Verimi6%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 15:19 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2025/08/31 |
| Yıllık Kazançlar | 2024/11/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Gerresheimer AG 35 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jonathon Unwin | Barclays |
| Pallav Mittal | Barclays |
| Gaurav Jain | Barclays |